Other substances

rLVS ΔcapB/SCoV2 MN

An experimental COVID-19 bacterium-vectored vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

rLVS ΔcapB/SCoV2 MN is an experimental COVID-19 vaccine based on highly attenuated Francisella tularensis subsp. holarctica vector, which is an intracellular bacterium capable to replicate inside host macrophages. It produces SARS-CoV-2 M and N fusion protein. Administered in two intranasal or intradermal doses, it protected hamster model in a viral challenge from severe weight loss and lung pathology and reduced viral replication in lungs and oropharynx (Jia et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
Nucleocapsid protein Membrane protein Animal model Mixed substance 		golden Syrian hamsters 5.70

Administered in two intranasal or intradermal doses, the vaccine protected hamster model in a viral challenge from severe weight loss and lung pathology and reduced viral replication in lungs and oropharynx.

 Mar/30/2021
Export (.csv)